Parent Study: A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism Sub-study: A Follow-up Substudy After Completion of the BaxPA Main Study.
A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 212 participants.
Also called NCT07007793
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 212 participants
- Sponsor
- Registry
-
NCT07007793
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Australia, Canada, China, France, Germany, India, Italy, Japan, Spain, Taiwan, United Kingdom
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT07007793. Randomized; quadruple masking; primary purpose treatment. Start 2025-08-07 (actual); primary completion 2027-07-27 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Parent Study: A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism Sub-study: A Follow-up Substudy After Completion of the BaxPA Main Study.
- Acronym
- BaxPA
- Condition
- Primary Hyperaldosteronism
- Intervention (Drug)
- Baxdrostat
- Intervention (Drug)
- Placebo
- Lead sponsor
- AstraZeneca
Record details
- Record id
cardio:ct-nct07007793- Content hash
7013a20c3bc7efb707daafa3d3c6aff64bfd32a77ff3e9f700e72849424d8978